In the recent years, multiple preclinical studies in animal models of glioma have demonstrated that disrupting the CXCL12/CXCR4 pathway by specific antagonists affects tumor growth, vasculogenesis and post-radiation recurrence, suggesting that this approach represents a promising strategy for glioblastoma therapy [25–28]. This evidence concerns the gene CXCL12 and central nervous system cancer.